论文部分内容阅读
目的分析紫杉醇铂剂联合尼妥珠单抗并同步放化疗治疗中晚期鼻咽癌的临床效果。方法选取2010年7月至2011年6月南阳医学高等专科学校第一附属医院收治的鼻咽癌患者48例,均给予调强适形放射治疗及紫杉醇等化疗,而观察组再给予尼妥珠单抗治疗,观察治疗效果。结果对照组CR10例,PR6例,总有效率66.7%,观察组CR16例,PR6例,总有效率91.7%,观察组总有效率高于对照组,且差异具有统计学意义(χ2=4.547,P<0.05)。而且治疗后两组患者恶心呕吐,白细胞下降等不良反应发生率无统计学差异(P>0.05)。结论紫杉醇铂剂联合尼妥珠单抗并同步放化疗治疗中晚期鼻咽癌临床效果满意,建议在临床治疗中推广应用。
Objective To analyze the clinical effect of paclitaxel combined with nimotuzumab and concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods Forty-eight patients with nasopharyngeal carcinoma admitted to the First Affiliated Hospital of Nanyang Medical College from July 2010 to June 2011 were treated with IMRT and paclitaxel, while those in the observation group received nilotin Monoclonal antibody therapy to observe the therapeutic effect. Results The total effective rate was 66.7% in CR10 cases and PR6 cases in control group. The total effective rate was 91.7% in CR6 cases and PR6 cases in observation group. The total effective rate in observation group was higher than that in control group (χ2 = 4.547, P <0.05). And no significant difference was found in the incidence of adverse reactions such as nausea and vomiting, leukopenia between the two groups after treatment (P> 0.05). Conclusion paclitaxel platinum agent combined with nimotuzumab and concurrent chemoradiotherapy in the treatment of advanced nasopharyngeal carcinoma clinical results are satisfactory, it is recommended in the clinical treatment of the promotion and application.